GlaxoSmithKline and Medicago have initiated late-stage testing of their investigational plant-based adjuvanted coronavirus vaccine that was granted fast track status by the FDA last month. Up to 30,000 health participants will be enrolled in the Phase 3 study that will assess the use of two vaccine doses administered 21 days apart.